GHK-Cu vs AHK-Cu (Copper Peptides)
GHK-Cu and AHK-Cu are the two most-discussed copper peptides in cosmeceutical and hair-loss formulations. They share the same copper-binding architecture — a histidine-lysine C-terminus that coordinates a copper(II) ion — but they differ at the first amino acid (glycine vs alanine), and that single residue swap correlates with meaningfully different research profiles. GHK-Cu is the extensively studied skin and wound-healing copper peptide; AHK-Cu has a narrower, hair-focused evidence base. Despite the surface similarity, treating them as interchangeable overstates what the AHK-specific evidence actually supports.
GHK-Cu
The most-studied copper peptide in skincare — a naturally occurring tripeptide (GHK, Gly-His-Lys) whose active tissue form is the copper complex GHK-Cu, with extensive evidence for skin remodeling, collagen synthesis, wound healing, and anti-aging.
AHK-Cu
A copper peptide — the copper-complexed tripeptide alanine-histidine-lysine (AHK-Cu, Copper Tripeptide-3) — studied for hair follicle stimulation and dermal papilla cell survival. A structural cousin of the better-known copper peptide GHK-Cu with a distinct, hair-focused research profile.
| Category | GHK-Cu | AHK-Cu |
|---|---|---|
| Sequence | Glycyl-L-Histidyl-L-Lysine (GHK) bound to Cu²⁺ | L-Alanyl-L-Histidyl-L-Lysine (AHK) bound to Cu²⁺ |
| Alternative Names | Copper Tripeptide-1, Copper Peptide, Pickart's Peptide, Glycyl-Histidyl-Lysine Copper | Copper Tripeptide-3, AHK Copper Peptide, Ala-His-Lys Copper Complex |
| Discovery | Isolated by Loren Pickart in 1973 from human plasma while investigating youthful protein-synthesis factors | Structure-activity variant developed in the copper-tripeptide family; hair-follicle activity characterized by Pyo et al. in 2007 |
| Primary Research Focus | Skin remodeling, collagen synthesis, wound healing, gene-expression modulation (Connectivity Map: ~4,000+ genes) | Hair follicle elongation, dermal papilla cell proliferation, anti-apoptotic signaling (Bcl-2/Bax, caspase-3, PARP) |
| Evidence Depth | Moderate — decades of in vitro, ex vivo, and human clinical work; RCTs on post-CO₂ laser-resurfacing wound healing | Preliminary — a single foundational in vitro and ex vivo study (Pyo et al., 2007) with thin independent replication; no published human clinical trials |
| Overall Confidence (Site Rating) | ~70% — one of the best-characterized peptides in cosmetic dermatology | ~20% — mechanistically interesting but clinically unproven; single-study foundation is a notable limitation |
| Human Clinical Data | Multiple topical RCTs for photoaging, post-laser healing, and anti-aging endpoints; decades of post-marketing cosmetic use | None published for AHK-Cu or Pal-AHK for any endpoint — hair growth, skin anti-aging, pigmentation, or otherwise |
| Key Mechanistic Signatures | Upregulates collagen I/III, decorin, and ECM components; activates metalloproteinases; stimulates angiogenesis and antioxidant response; modulates ubiquitin-proteasome clearance of damaged proteins | Elevates Bcl-2/Bax ratio in dermal papilla cells; reduces cleaved caspase-3 (~43%) and cleaved PARP (~78%) at 10⁻⁹ M; stimulates VEGF and suppresses TGF-β1 in fibroblasts |
| Typical Use Case | Topical anti-aging serums and creams; post-procedure wound-healing acceleration; professional dermatology formulations | Topical hair-loss serums and scalp tonics; multi-peptide cosmetic blends targeting follicular biology |
| Cosmetic Ingredient Form | GHK-Cu is the cosmetic-ingredient form, typically 1–3% in serums and creams (higher concentrations produce a visible blue tint) | Pal-AHK (palmitoyl tripeptide-28 / palmitoyl tripeptide-3) is the cosmetic-ingredient form — palmitoylation improves transdermal penetration; concentrations in finished products are rarely disclosed |
| Injectable / Compounded Availability | Injectable GHK-Cu is compounded and used in some clinical settings for systemic or intradermal delivery, though clinical evidence for this route is much thinner than for topical use | No established injectable category in humans; research-grade AHK-Cu is used in topical and mesotherapy contexts but not as a systemic injectable |
| Penetration Characteristics | Small (~340 Da) and moderately permeable through stratum corneum; formulation vehicle (liposomal, microneedle, penetration enhancers) materially affects dermal delivery | Palmitoylated Pal-AHK form is designed for transdermal delivery; plain AHK-Cu (non-lipidated) has poor passive skin permeation on its own |
| Safety Profile | Well-tolerated in topical cosmetic use; rare contact dermatitis; avoid in Wilson's disease; no significant adverse signal in decades of market data | Limited safety data specific to AHK-Cu; topical use in cosmetic formulations appears well-tolerated but without the decades of surveillance GHK-Cu has; same Wilson's disease caution applies |
| Regulatory Status | Widely permitted as a cosmetic ingredient globally (EU CosIng, UK, Canada, Australia, Japan); not FDA-approved as a drug | Permitted as a cosmetic ingredient across major markets under the palmitoyl tripeptide-28 / copper tripeptide-3 designations; not FDA-approved as a drug |
| Relative Cost | Mature market; many product tiers from mass-market to professional dermatology | Niche market; often sold within multi-peptide hair-growth formulations rather than as a standalone product |
| Formulation Compatibility | Incompatible with high-concentration vitamin C (L-ascorbic acid) and strong AHA/BHA exfoliants when co-applied in the same layer — low pH destabilizes the copper complex. Separate to different times of day. | Same compatibility rules apply — copper-peptide complexes destabilize under low-pH exposure. Multi-peptide formulations often combine AHK-Cu or Pal-AHK with GHK-Cu, matrikines, caffeine, or biotin. |
Summary
Think of GHK-Cu and AHK-Cu as cousins in the copper peptide family who have taken different career paths. Both are tripeptides with histidine and lysine at positions two and three, both form stable square-planar copper complexes, and both appear in cosmeceutical marketing under variants of 'copper peptide.' But the first amino acid — glycine in GHK, alanine in AHK — is associated with divergent biology in the published literature, and the two peptides have very different evidence bases. GHK-Cu is the copper peptide that built the category. Isolated by Loren Pickart in 1973, it has decades of in vitro, ex vivo, animal, and human clinical work behind it. The mechanistic characterization is unusually deep — a Broad Institute Connectivity Map analysis documented gene-expression effects across roughly 4,000 human genes, including coordinated upregulation of collagen synthesis, decorin, metalloproteinases, and antioxidant pathways, plus modulation of the ubiquitin-proteasome system. Clinically, topical GHK-Cu has human RCT evidence for post-CO₂ laser resurfacing wound healing and multiple trials on photoaging endpoints. It sits at roughly 70% confidence on this site's evidence rating — one of the better-characterized copper peptides in cosmetic dermatology. AHK-Cu is a different story. The mechanistic case for hair-follicle activity is biologically interesting: a 2007 in vitro and ex vivo study by Pyo et al. demonstrated that AHK-Cu at picomolar to nanomolar concentrations stimulated human hair follicle elongation and dermal papilla cell proliferation, with clear anti-apoptotic signatures (elevated Bcl-2/Bax ratio, ~43% reduction in cleaved caspase-3, ~78% reduction in cleaved PARP at 10⁻⁹ M), plus VEGF upregulation and TGF-β1 suppression in fibroblasts. That is a credible molecular-level mechanism for promoting anagen-phase hair growth. The problem is that this remains essentially a single-study foundation. Independent peer-reviewed replication is thin, no in vivo animal hair-growth models have been published, and no human clinical trial exists for AHK-Cu or Pal-AHK (the palmitoylated cosmetic form) for any endpoint. Site confidence sits around 20% — the mechanism is plausible, the clinical evidence is not yet there. The practical implication for formulations: GHK-Cu is where you go for collagen, wound-healing, and general anti-aging copper-peptide benefit, and the evidence actually supports the use. AHK-Cu is where you go if you specifically want the hair-follicle mechanism, and the evidence supports that it is biologically interesting but does not yet support strong efficacy claims. Multi-peptide cosmetic blends frequently combine both — GHK-Cu for the skin layer, AHK-Cu or Pal-AHK for the follicular layer — on the theory that they engage complementary pathways without interfering with each other, though no controlled head-to-head or combination-vs-single-peptide human trial has tested that theory. Neither is a substitute for FDA-approved hair-loss or anti-aging interventions. For androgenetic alopecia, minoxidil and finasteride carry incomparably stronger evidence bases. For photoaging, topical tretinoin remains the most evidence-supported single active. Copper peptides complement these approaches as adjunct cosmetic actives rather than replacing them. Formulation compatibility matters for both: keep high-concentration vitamin C, glycolic acid, and other strong low-pH actives separate from copper-peptide products, because acidic environments destabilize the copper complex that makes these peptides biologically interesting in the first place.
These peptides are often used together. See our stack profiles for combination details.